Valtech Cardio develops minimally-invasive surgical and transcatheter mitral valve repair and replacement technologies intended to correct or significantly improve mitral valve function and reduce or eliminate mitral regurgitation (MR). The company’s products target MR, a serious heart disorder characterized by incomplete closure of the mitral valve. Valtech completed a $17.8M Series B financing to advance its programs. According to Founder and COO Amir Gross, the funding will be used to complete development and initial clinical evaluation of several products. The company is based in Or Yehuda, Israel, with a U.S. office in Waltham, Massachusetts. The article does not disclose prior rounds, revenues, or user metrics.

Total raised

$18M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2010